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Abstract
Background: We determined whether the market exclusivity incentive of the European Orphan Drug Regulation
results in a market monopoly or that absence of another Orphan Medicinal Product (OMP) for the same rare
disorder, a so-called follow-on OMP, is a matter of time or market size. In the interest of rare disorder patients
better understanding of the effect of the market exclusivity incentive on follow-on OMP development is warranted.
Methods: First, the impact of various market-, product- and disease-related characteristics on follow-on OMP
development in the EU was determined by comparing rare disorders with an approved OMP and at least one
follow-on OMP (N = 26), with rare disorders with an approved OMP and no follow-on OMP (N = 18). Next, we
determined whether manufacturers continued development of a follow-on OMP upon approval of the first OMP
for the intended rare disorder. Since in the EU significant benefit of an OMP has to be established, we determined
for each follow-on OMP for which development was continued on what grounds significant benefit was assumed
by the sponsor. Data were collected from the public domain only.
Results: The likelihood of a rare disorder with an approved OMP to obtain at least one follow-on OMP
development was strongly associated with disease prevalence, turnover of the first OMP, disease class, disease-
specific scientific output and age of onset. Out of a total of 120 follow-on OMPs only one follow-on OMP could be
identified for which development was discontinued upon approval of the first OMP for the same rare disorder.
Only a substantial level of discontinuation of follow-on OMP development would have indicated the existence of a
market monopoly. Moreover, sponsors that continued development of a follow-on OMP predominantly assumed
that their product had an improved efficacy compared to the first approved OMP.
Conclusions: This study provides evidence that absence of follow-on OMP development is a matter of time or
market size, rather than that the market exclusivity incentive of the European Orphan Drug Regulation creates a
market monopoly.
Background
The current estimate of number of rare disorders is
6,000 to 8,000, many of which are of genetic origin, and
affect children at a very early age. In the United States
(US), a rare disease is defined as a disease that affects
less than 200,000 inhabitants [1]. In the EU, besides
affecting fewer than five per 10,000 inhabitants, a rare
disease needs to be life-threatening or chronically debili-
tating [1]. The total number of patients in Europe and
the US suffering from a rare disorder is estimated at 55
million, and as such rare disorders are considered a real
health issue [2,3]. Because of the rarity, the cost of
developing and marketing a medicinal product to diag-
nose, treat or prevent a rare condition would not be
recovered by the expected sales of the medicinal product
under normal market conditions. Therefore, in several
jurisdictions specific legislation has been introduced to
stimulate the development of drugs for rare diseases, so-
called orphan drugs [4,5].
Since the European Union (EU) Regulation on Orphan
Medicinal Products (OMP) came into force in 2000,
more than 60 Orphan Medicinal Products (OMPs) have
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inal products have received an orphan designation (OD)
in the EU within the first decade of this regulation [6,7].
Just like the United States Orphan Drug Act [8-10], the
EU Orphan Drug Regulation is highly appreciated for its
role in creating a favorable orphan drug development
environment [10,11]. However, this apparent success of
the legislations has also been questioned. Joppi et al.
argued that the large number of designated orphan
drugs may provide false hope to patients with a rare dis-
order, because only a small percentage of these desig-
nated orphan drugs have obtained marketing approval
in the EU [12,13]. Moreover, both in the EU and US,
certain disease classes - in particular oncology - are
associated with a high number of orphan designations
and approvals [9,14,15]. In brief, the development of
orphan drugs is stimulated through a number of regula-
tory and economic incentives, of which a market exclu-
sivity period of seven and ten years in the US and the
EU, respectively, is regarded the foremost one [1,14].
Recently, Roos et al. claimed that the highly praised
market exclusivity incentive basically creates a market
monopoly that in their view has allowed manufacturers
to charge ‘exorbitant’ prices for orphan drugs [16]. Tam-
buyzer in contrast argued that “if an approved OMP is
currently the only product on the market, it is either
because a company was the first to develop a treatment
for this disease and competitors have yet to enter the
market or because the market is too small to attract
competition, rather than because the incentives have
created a monopoly” [ 1 7 ] .T oo u rk n o w l e d g et h e
hypothesis that the market exclusivity incentive serves
as a disincentive for the development and marketing of
another OMP, a so-called follow-on OMP, next to the
first approved OMP has never been tested before.
Review of the EU Community Register for Orphan
Medicinal Products revealed that for several rare disor-
ders with an approved OMP no other OMPs have been
approved or are currently under development [6]. How-
ever, it also revealed that for some other rare disorders
in the EU one or more OMPs have been approved next
to the first OMP. For example, sildenafil, sitaxentan, ilo-
prost and ambrisentan have all been approved as treat-
ment for pulmonary arterial hypertension next to
bosentan, the first OMP [6]. In the EU it is allowed to
approve a follow-on OMP next to the first OMP, pro-
vided that significant benefit to those affected by the
condition can be established. According to Commission
Regulation (EC) No 847/2000 [18], significant benefit
means a clinically relevant advantage or a major contri-
bution to patient care, and is generally justified by
“demonstration of potentially greater efficacy, an
improved safety profile and/or more favorable pharma-
cokinetic properties than existing methods” [19].
Taking the aforementioned into account it remains
unclear whether the market exclusivity incentive serves
as a disincentive for follow-on OMP development or
not. Therefore, the objective of this study was to deter-
mine whether the market exclusivity incentive of the EU
Orphan Drug Regulation results in a market monopoly
as argued by Roos et al. [16], or that absence of a fol-
low-on OMP for a rare disorder for which already an
approved OMP exists in the EU is a matter of time or
market size as claimed by Tambuyzer [17]. First, the
impact of various market-, product- and disease-related
characteristics on follow-on OMP development was
determined by comparing rare disorders with an
approved OMP and at least one follow-on OMP, with
rare disorders with an approved OMP and no follow-on
OMP. Next, we determined whether manufacturers con-
tinued or discontinued development of a follow-on
OMP upon approval of the first OMP for the intended
rare disorder. The presence of considerable discontinua-
tion of follow-on OMP development would suggest the
existence of a market monopoly. Finally, since in the EU
significant benefit of an OMP has to be established, we
also determined for each follow-on OMP for which
development was continued on what grounds significant
benefit was assumed by the sponsor.
Methods
Characterization of rare disorders with an approved OMP
The study included all rare disorders that obtained at least
one approved OMP for the treatment of that rare disorder
in the EU between the start of the EU Regulation on
Orphan Medicinal Products (April 2000) and 31 Decem-
ber 2008. The study was limited to rare disorders with an
approved treatment, since only one rare disorder with an
approved OMP for the diagnosis or prevention of that dis-
order could be identified. For each rare disorder with an
approved OMP the EU register of Orphan Medicinal Pro-
ducts was checked for follow-on OMPs between the start
of the EU Regulation on Orphan Medicinal Products
(April 2000) and 30 April 2010. The reason for extending
the cut-off date was to maximize detection of follow-on
OMPs. A follow-on OMP was defined as: (a) another
approved OMP for the same rare disorder in Europe (e.g.
both agalsidase bèta and agalsidase alfa are approved for
the treatment of Fabry disease in Europe) or (b) another
medicinal product with a European orphan designation
(OD) for the same disorder. Only OMPs that were under
development at or after marketing approval of the first
OMP for the same rare disorder were identified as follow-
on OMP and included in the study. An OMP designated
before approval of the first OMP for the same rare disor-
der, but whose development was discontinued before
approval of the first OMP was not considered as follow-on
OMP. Finally, rare disorders included in the study were
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approved OMP and at least one follow-on OMP (’Follow-
on’ group), and (b) rare disorders having an approved
OMP, but no follow-on OMP (’no Follow-on’ group).
Factors elucidating follow-on OMP development
Data were collected for each rare disorder on product-,
market- and disease-related characteristics to get insight
in factors elucidating follow-on OMP development.
Selection of data was limited to the public domain and
essentially similar to Heemstra et al. [20,21].
Market-related characteristics included data on the
prevalence of the rare disorder, the annual turnover of
the first OMP, and whether the first OMP was desig-
nated or approved outside Europe. Product-related char-
acteristics included data on the pharmaceutical
formulation. Disease-related characteristics included
data on the disease class, the disease-specific scientific
output (i.e. the number of scientific publications) and
whether the rare disorder was a childhood, chronic or
inheritable disorder [20,21]. A full list of these charac-
teristics, definitions and the (main) public sources used,
is depicted in table 1.
The characteristics of rare disorders having at least
one follow-on OMP (’Follow-on’ group) and rare disor-
ders with no follow-on OMP (’no Follow-on’ group)
were compared using univariate analyses. Odds ratios
(OR) and 95% confidence intervals (CI) were calculated
for each characteristic. All analyses were done using
SPSS, version 16.0.
Effect of marketing authorization of first OMP on follow-
on OMP development
Upon marketing approval of a first OMP, sponsors of a
follow-on OMP for the same rare disorder could either
decide to continue or discontinue development. In this
study a sponsor continued development if: (a) the
orphan designation date of the follow-on OMP, based
on the EU orphan drug register, was after the date of
marketing authorization of the first OMP or (b) if conti-
nuation of development was verified in the public
domain for follow-on OMPs having a designation date
prior to the approval date of the first OMP. As a result,
the following two groups were discerned: (a) sponsors
that continued development of a follow-on OMP upon
marketing approval of the first OMP and (b) sponsors
that discontinued development of a follow-on OMP
upon marketing approval of the first OMP.
Characterization of assumptions of significant benefit of
follow-on OMPs
The European Medicines Agency (EMA) guideline
COMP/15893/2009 outlines the necessary level of evi-
dence to support assumptions of significant benefit [19].
Significant benefit is justified in the EU by demonstrat-
ing an improved efficacy, a better safety or a major con-
tribution to patient care. In this study the concept of
significant benefit included these three categories. Data
regarding the assumptions of significant benefit were
collected using sources in thep u b l i cd o m a i n .F i r s t l y ,
European Public Assessment Reports (EPARs) were con-
sulted for follow-on OMPs that were successfully devel-
oped and approved in the EU. An EPAR provides
information regarding the significant benefit of a follow-
on OMP compared to earlier approved OMPs for the
same rare disorder. Secondly, Summaries of Opinion
were consulted provided that the follow-on OMP
obtained an orphan designation after approval of the
first OMP for the same rare disorder. Finally, sponsor
documents (e.g. sponsor website, annual reports, press
releases) were consulted to determine the assumptions
of significant benefit of follow-on OMPs that obtained
an orphan designation before approval of the first OMP
for the same rare disorder. All collected assumptions of
significant benefit were compared and mapped using
central key words of the mentioned EMA guideline [19]
for each of the three categories (for example mechanism
of action for improved efficacy, side effects for better
safety and way of administration for a major contribu-
tion to patient care).
Results
Characterization of rare disorders with an approved OMP
From the start of the EU Regulation on Orphan Medic-
inal Products (April 2000) up to 31 December 2008, 58
OMPs intended for the treatment of a rare disorder
obtained marketing approval in the EU [6]. Although
some products (e.g. imatinib and dasatinib) have been
approved for more than one rare disorder, most
approved OMPs are intended as treatment for only one
specific rare disorder. Collectively, the 58 approved
OMPs have been authorized as treatments for 44 differ-
ent rare disorders. Of these 44 rare disorders, 26 had at
least one follow-on OMP (’Follow-on’ group) and 18 did
n o th a v eaf o l l o w - o nO M P( ’no Follow-on’ group), as
reflected in table 2.
A review of the EU Community Register of Orphan
Medicinal Products revealed that the 26 rare disorders
in the ‘Follow-on’ group encompass a total of 163
orphan designations (ODs) between the start of the EU
Orphan Drug Regulation (April 2000) and 30 April 2010
in the EU [6]. Analysis of the 163 ODs showed that
development of 13 orphan drugs had been discontinued
before marketing approval of the first OMP for the
same rare disorder. In addition, one orphan drug was
intended for the diagnosis rather than for the treatment
of a rare disorder. From the remaining 149 ODs, 120
orphan drugs were identified as being under
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Page 3 of 11Table 1 Definitions and sources used for market-, product- and disease-related characteristics of Orphan Medicinal Products (OMPs)
Characteristic Definitions (Main) public source
Market-related characteristics
prevalence < 1 per 100,000
between 1 - 50 per 100,000
Orpha.net (report series, Nov 2009)
annual turnover first OMP maximum annual turnover of the first OMP Sponsor documents
first OMP designated outside EU first OMP obtained an orphan designation FDA Orphan Drug
inside and outside Europe Product database
first OMP authorized outside EU first OMP obtained marketing authorization FDA Orphan Drug
inside and outside Europe Product database
Product-related characteristics
pharmaceutical formulation parenteral
oral
EPARs
Disease-related characteristics
disease class (ICD-10) other ICD-10 classes
C00-D48 (oncologic disorders)
Orpha.net
disease-specific scientific output number of scientific publications in the period 1976-2008 in PubMed for a specific rare disorder PubMed
inheritable disease majority of cases caused by genetic inheritance Orpha.net
chronic disease disease duration is generally over 3 months Orpha.net
childhood disease majority of diagnosis before age 18 Orpha.net
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1Table 2 Rare disorders with an approved OMP in EU until 31 December 2008
Rare disorder
(N = 44)
First OMP
(INN-name)
Other ODs*
(N = 149)
Fabry disease agalsidase alfa/agalsidase beta** 1
Chronic myeloid leukemia imatinib 7
Gaucher disease miglustat 3
Acute promyelocytic leukemia arsenic trioxide 2
Pulmonary arterial hypertension bosentan 12
Acromegaly pegvisomant 2
Gastrointestinal stromal tumors imatinib 3
Familial adenomatous polypopsis celecoxib 2
NAGS-deficiency carglumic acid -
Treatment prior to hematopoietic progenitor cell
transplantation busulfan -
Mucopolysaccharidosis type I laronidase -
Essential thrombocythaemia anagrelide -
Wilson’s disease zinc acetate dihydrate 1
High-grade dysplasia in Barrett’s oesophagus porfimer sodium -
Patent ductus arteriosus ibuprofen -
Adrenal cortical carcinoma mitotane 1
Hairy cell leukemia cladribine 1
Narcolepsy-cataplexy sodium oxybate 1
Chronic pain requiring intraspinal analgesia ziconotide -
Tyrosinaemia type I (hereditary) nitisinone -
Dermatofibrosarcoma protuberans imatinib -
Acute lymphoblastic leukemia clofarabine 16
Anthracycline extravasations dexrazoxane -
Renal cell carcinoma sorafenib 18
Mucopolysaccharidosis type VI galsulfase -
Glycogen storage disease type II alglucosidase alpha 1
Chronic iron overload requiring chelation therapy deferasirox 2
Hypereosinophilic syndrome imatinib 1
Myelodysplastic syndromes imatinib 7
Hepatocellular carcinoma sorafenib 9
Soft tissue sarcoma trabectedin 7
Paroxysmal nocturnal haemoglobinuria eculizumab -
Sickle cell syndrome hydroxycarbamide 3
Multiple myeloma lenalidomide 14
Lennox-Gastaut syndrome rufinamide -
Severe primary IGF-1 deficiency mecasermin -
Mucopolysaccharidosis type II idursulfase -
Severe myoclonic epilepsy in infancy (Dravet’s syndrome) stiripentol -
Homocystinuria betaine anhydrous -
Systemic sclerosis bosentan 3
Chronic myelomonocytic leukemia azacitidine -
Hyperphenylalaninaemia sapropterin dihydrochloride 2
Angioedema (hereditary) icatibant 3
Acute myeloid leukemia histamine dihydrochloride 27
* Other ODs in the EU under development for treatment of the specific rare disorder between the start of the EU Orphan Drug Regulation (April 2000) and 30
April 2010.
** Both agalsidase alfa and agalsidase beta obtained market approval at the 3th of August 2001 in the EU.
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Page 5 of 11development at or after approval of the first OMP and
included as follow-on OMP in this study. Despite an in
depth search into multiple sources in the public domain,
for the remaining 29 ODs we were unable to determine
whether these orphan drugs were still under develop-
ment at or after approval of the first OMP for the same
rare disorder. Consequently, these ODs could not be
identified as follow-on OMPs and were not included in
the study.
Factors elucidating follow-on OMP development
The results of the univariate comparisons between rare
disorders with an approved OMP and at least one fol-
low-on OMP (n = 26) and rare disorders with an
approved OMP and no follow-on OMP (n = 18) are
shown in table 3. For some of the characteristics statisti-
cally significant relations were observed, however, the
association was strongest for the scientific output of a
specific disorder. A rare disorder with more than 450
scientific publications in PubMed in the period 1976-
2008 was associated with a 25-fold increase in the
chance to obtain at least one follow-on OMP compared
to a rare disorder with less than 450 scientific publica-
tions in this period (OR = 25.0; CI = 2.8-226.1). Further-
more, the results showed that oncologic disorders (ICD-
10 class C00-D48) with an approved OMP have an 8-
fold increased likelihood to obtain at least one follow-on
OMP compared to rare disorders in other ICD-10
classes (OR = 8.0; CI = 1.5-42.0). A statistically signifi-
cant relation was also found for the annual turnover of
the first approved OMP. Rare disorders having a first
approved OMP with more than 50 million US dollar
annual sales have an almost 5-fold higher probability to
obtain a follow-on OMP than rare disorders having a
first approved OMP with annual sales below 50 million
US dollar (OR = 4.8; CI = 1.1-21.4). Finally, a striking
result is that rare disorders with an age of onset in
childhood have a 5-fold lower chance to obtain at least
one follow-on OMP than rare disorders with an age of
onset in adulthood (OR = 0.2; CI = 0.1-0.8).
The descriptive statistics showed a strong association
between the disease prevalence and the likelihood to
obtain at least one follow-on OMP. All rare disorders
with a first approved OMP and at least one follow-on
OMP had a prevalence between 1/100,000 and 50/
100,000, whereas rare disorders with a first approved
OMP and no follow-on OMP were more or less equally
divided over both prevalence categories (< 1/100,000
and 1-50/100,000).
Effect of marketing authorization of first OMP on follow-
on OMP development
To elucidate whether the instrument of market exclusiv-
ity served as disincentive, we determined the effect of
marketing authorization of a first OMP on follow-on
development. Overall, our results show that develop-
ment of follow-on OMPs is continued after marketing
approval of a first OMP for the same rare disorder. Out
of a total of 120 follow-on OMPs only one follow-on
OMP, PI-88 of the Australian company Progen, could
be identified for which development was discontinued.
According to the company the decision of discontinua-
tion “was made based on a number of factors, but was
primarily driven by the competitive pressures in Europe
and North America of Bayer’s launching a Nexavar
®
trial amongst the same patients” [22].
Characterization of assumptions of significant benefit of
follow-on OMPs
Assumptions of significant benefit were found for 106 of
the 119 follow-on OMPs in the EU. For the remaining
13 follow-on OMPs no assumptions of significant bene-
fit could be identified, predominantly due to lack of
information in sponsor documents for follow-on OMPs
that obtained an orphan designation (OD) before mar-
keting approval of the first OMP (n = 10). For the other
three follow-on OMPs the Summary of Opinion did not
provide clear information regarding the assumption of
significant benefit (e.g. “the product might be of poten-
tial significant benefit”). Consequently, these follow-on
OMPs were not included in the study.
For several follow-on OMPs (n = 22) more than one
assumption of significant benefit was found, resulting in
a total of 130 different assumptions, as depicted in table
4. Most assumptions of significant benefit (85.5%; n =
111) were related to the concept of improved efficacy.
Within this category, most sponsors assumed that their
follow-on OMP would be of significant benefit due to a
different mechanism of action, followed by treatment of
a subgroup of patients. The assumptions of significant
benefit for the remaining 19 follow-on OMPs were
related to an improved safety profile (n = 9) or a major
contribution to patient care (n = 10) in comparison with
t h ef i r s tO M Pf o rt h es a m er a r ed i s o r d e r ,r e s p e c t i v e l y .
More than half of the follow-on OMPs in the category
of improved safety were assumed to have fewer side
effects compared to existing treatments. With regard to
the contribution to patient care it was observed that,
except for one follow-on OMP, all assumptions were
related to the mode of administration.
Discussion
In the interest of patients with a rare disorder, but also
of other stakeholders, better understanding of the effect
of the market exclusivity incentive on follow-on OMP
development for a rare disorder for which an approved
OMP exists is warranted. The objective of this study
was to determine whether the market exclusivity
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Page 6 of 11Table 3 Comparison between rare disorders with follow-on and no follow-on OMPs: Descriptive statistics and univariate analyses
Characteristic Indicator Rare disorders
Total
N=4 4
’Follow-on’ Group
N=2 6
’No Follow-on’ Group
N=1 8
Odds Ratio (95% Confidence Interval)
Market-related
prevalence < 1 per 100,000 9 0* 9 reference level
between 1 - 50 per 100,000 34 26 8 not applicable
turnover first < 50 mil. US $ 11 4 7 reference level
OMP > 50 mil. US $ 26 19 7 4.8 (1.1-21.4)
designated outside no 8 5 3 reference level
EU yes 36 21 15 0.8 (0.2-4.1)
approved outside no 11 7 4 reference level
EU yes 33 19 14 0.8 (0.2-3.2)
Product-related
pharmaceutical parenteral 20 9 11 reference level
formulation oral 24 17 7 3.0 (0.9-10.3)
Disease-related
disease class other ICD-10 classes 29 13 16 reference level
C00-D48 15 13 2 8.0 (1.5-42.0)
disease-specific < 450 publications 10 1 9 reference level
scientific output > 450 publications 34 25 9 25.0 (2.8-226.1)
childhood adulthood 22 17 5 reference level
childhood 17 7 10 0.2 (0.1-0.8)
chronic non-chronic 5 3 2 reference level
chronic 34 19 15 0.8 (0.1-5.7)
inheritable non-inheritable 28 18 10 reference level
inheritable 16 8 8 0.6 (0.2-1.9)
* Zero cell count/no follow-on OMP
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1incentive of the EU Orphan Drug Regulation results in a
market monopoly, as argued by Roos et al. [16], or that
absence of follow-on OMPs is a matter of time or mar-
ket size, as claimed by Tambuyzer [17]. First, the impact
of various market-, product- and disease-related charac-
teristics on follow-on OMP development in the EU was
determined. Comparison of rare disorders with a first
approved OMP and at least one follow-on OMP (’Fol-
low-on’ group) with rare disorders with a first approved
OMP and no follow-on OMP (’no Follow-on group’)
revealed disease prevalence, turnover of the first OMP,
disease class, disease-specific scientific output and age of
onset as predictors of follow-on OMP development.
Although it was not possible to perform a multivariate
analysis and to test whether any of the aforementioned
characteristics were mutually related, it is suspected that
some level of mutual relationship may exist. Heemstra
et al. showed that scientific output for oncologic rare
disorders in general is higher than for other rare disor-
ders, which suggests some degree of mutual relationship
between disease class and scientific output [20]. Also,
the prevalence of a rare disorder and turnover of the
first OMP may to some extent be mutually related.
Despite the possibility of mutual relationships, our find-
ings are in line with several studies that focused on
characteristics that play a driving role in the orphan
drug development process [20,23-25].
The lower likelihood on follow-on OMP development
for rare childhood disorders is most likely a natural con-
sequence of the general reluctance of the pharmaceuti-
cal industry to invest in the development of specific
therapies for a population that is small in number and
fragmented into several age groups with often unique
requirements [26,27]. To stimulate paediatric drug
development in the EU Regulation (EC) No 1901/2006
on medicinal products for paediatric use came into
force in January 2007 [28]. Through a number of regula-
tory and economic incentives, including extension of the
market exclusivity period from ten to twelve years for
OMPs intended for a paediatric indication, the legisla-
tion intends to have a positive impact on paediatric
drug development, although risks and pitfalls remain
[29]. Conducting clinical trials for rare indications, espe-
cially very rare ones, remains difficult due to a number
of well-known practical limitations (e.g. lack of proper
diagnosis, finding enough patients, geographical distri-
bution of patient population) [30]. Successful drug
development requires thorough disease knowledge, such
as its etiology and pathophysiology [25]. The latter
explains our finding that, next to initiation of an orphan
drug development program [20], the level of disease-
specific scientific output increases the likelihood on fol-
low-on OMP development. It also explains our observa-
tion that for rare oncologic diseases the likelihood on
follow-on OMP development is higher than for other
ICD disease classes. Considerable public and private
expenditure on research and a high-level of transna-
tional research infrastructure have resulted in oncology
having the highest scientific output in the area of rare
diseases [31,32]. Consequently, oncology represents an
attractive indication for the pharmaceutical sector
[33,34], resulting in the highest number of first and fol-
low-on OMPs in development as well as approved [6].
Because of its dynamic and divergent nature, biomedical
research can result in several competing hypotheses on
the possible causes of diseases, and several promising
targets and therapeutical approaches [35]. This makes
biomedical research an extremely complex process to
Table 4 Assumptions of significant benefit of the follow-on OMPs for which development was continued
Category of significant benefit Classes of significant benefit Assumptions
N = 130 %
Improved efficacy Different mechanism of action 47 36.2
Sub-group (including patients who do not respond
on current treatments) 27 20.8
Alternative/additional treatment 14 10.8
Improve the long-term outcome of the patient 12 9.2
More effective (unspecified) 10 7.7
Improve the treatment (unspecified) 1 0.8
Total 111 85.5
Improved safety Fewer side effects 5 3.8
Increased tolerability 2 1.5
Improved safety (unspecified) 2 1.5
Total 9 6.8
Contribution to patient care Mode of administration 9 6.9
Wider availability 1 0.8
Total 10 7.7
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into (follow-on) OMP development requires time.
In contrast to the claim by Roos et al. that the market
exclusivity incentive basically creates a market monopoly
that in their view allows manufacturers to charge ‘exor-
bitant’ prices for orphan drugs [16], we found that turn-
over of the first OMP in fact increases the likelihood on
follow-on OMP development. The presence of an
approved OMP for a rare disorder is a clear indication
that development and marketing of a therapy for that
specific rare disorder is attainable. However, the mere
presence of an approved OMP for a rare disorder is not
sufficient; a certain level of profitability is apparently an
important prerequisite for the initiation or continuation
of the development of a follow-on OMP.
Our finding that prevalence of a rare disease is asso-
ciated with an increased likelihood on follow-on OMP
development provides corroborative evidence for an ele-
ment in Tambuyzer’sh y p o t h e s i st h a ti fa na p p r o v e d
OMP is currently the only product on the market, this
can be explained because the market is too small to
attract competition [17]. Acemoglu and Linn more gen-
erally revealed that an increase in the potential market
size for a drug category correlates with an increase in
the number of new drugs in that category [24]. The
importance of prevalence of a rare disease, which can be
regarded as a surrogate marker for market size, was
already confirmed in other stages of the orphan drug
development process. Heemstra et al. showed that pre-
valence is a predictor for the translation of rare disorder
research into the initiation of an orphan drug develop-
ment program [20]. Yin reported that “the US Orphan
Drug Act has led to a significant and sustained increase
in new trials” among more prevalent rare diseases, but
not for less prevalent rare diseases [23].
Tambuyzer’sh y p o t h e s i si sf u r t h e rs u p p o r t e db yo u r
finding that in the EU all manufacturers of follow-on
OMPs upon approval of the first OMP for the same
rare disorder decided to continue development of their
product, except for one. Only a substantial level of dis-
continuation of follow-on OMP development would
have indicated the existence of a market monopoly. Dis-
continuation of several follow-on OMPs was found,
however, reasons for discontinuation were related to
conducting clinical trials, focus on another more pro-
mising indication, registrati o nf a i l u r ea n dl a c ko ff u n d -
ing. Apparently, discontinuation of follow-on OMPs is
not directly associated with market approval of a first
O M Pf o rt h es a m er a r ed i s o r d e r ,b u tr a t h e rd u et o
safety-, efficacy-, or economic-related factors similar to
the majority of regular drug development discontinua-
tion [36]. Interestingly, we found that 15 of the 120 fol-
low-on OMPs (12.5%) subsequently obtained a
marketing authorization in the EU between the start of
the legislation and April 2010. This is considerably
higher than the 45 of 528 orphan designations (8.5%)
that were approved in the EU between the start of the
legislation and 2007 [12]. One explanation for this
observation could be that the majority of follow-on
OMPs is in development by large pharmaceutical firms
(data not shown), whereas most orphan designated pro-
ducts are being developed by Small and Medium-sized
Enterprises (SMEs) [37]. In general, SMEs have less
experience in (orphan) drug development, which was
reported by Heemstra et al. as an important predictor
for OMP approval [21].
Finally, we found that sponsors that continue develop-
ment of a follow-on OMP in the EU predominantly
assume that their product has an improved efficacy com-
pared to the first OMP. Establishing the assumption of
significant benefit based on an improved safety and/or
major contribution to patient care may be either more
difficult for or less attractive to manufacturers of follow-
on OMPs. The EMA guideline on significant benefit
mentions that “a theoretical risk with an authorized pro-
duct cannot be compared with a theoretical lack of risk
with the product under development” [19]. However,
most applications for an orphan designation by a sponsor
are done in the late preclinical or early clinical testing
stage, which doesn’t include extensive human safety test-
ing. Moreover, serious adverse events with authorized
orphan medicinal products have been limited until now
[38]; only sitaxentan was voluntarily withdrawn from the
market by Pfizer in 2010 due to new information on two
cases of fatal liver injury [39]. The reason for the limited
number of follow-on OMPs with significant benefit based
on an assumption of a major contribution to patient care
may be best explained by a current lack of interest by the
pharmaceutical industry. Increased patient involvement
and demand may result in shifting focus to novel innova-
tive drug delivery systems that will allow more selective,
more precise, less frequent dosing of the orphan medic-
inal product [40,41].
Conclusion
T h i ss t u d yp r o v i d e se v i d e n c ef o rt h eh y p o t h e s i st h a t
approval of the first OMP for a rare disorder, and con-
sequently a market exclusivity period of ten years, does
not serve as a disincentive for the development and
marketing of a follow-on OMP for the same indication
in the EU. We found that absence of follow-on OMP
development is more a matter of time or market size as
argued by Tambuyzer [17], rather than the creation of a
market monopoly as claimed by Roos et al. [16]. Apart
from market size, turnover of the first OMP, disease
class, disease-specific scientific output and age of onset
were identified as additional predictors of follow-on
OMP development. In general, regardless of approval of
Brabers et al. Orphanet Journal of Rare Diseases 2011, 6:59
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Page 9 of 11the first OMP for the intended rare disorder, develop-
ment of a follow-on OMP is continued and primarily
based on the assumption of improved efficacy.
F i n a l l y ,w i t h i nt h ea r e ao fr a r ed i s e a s e st h er o l eo f
patient organizations is strong, a real added value, and
continuously growing [40,41]. It will be interesting to
monitor if this increased patient involvement and
demand will result in expanding the focus of the phar-
maceutical industry to novel innovative drug delivery
systems that will allow more selective, more precise, less
frequent dosing of the orphan medicinal product [40].
Ultimately, we believe that, next to improved efficacy,
this kind of follow-on OMP development truly repre-
sents an important improvement in current care of
patients with a rare disorder.
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